Navigation Links
Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Date:10/18/2007

attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target tumor cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, which has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.

About MT103 (MEDI-538)

MT103, which is being co-developed with MedImmune as MEDI-538, is a BiTE(R) antibody being developed with the intent to treat patients with certain types of B-cell lymphomas. MT103 received orphan drug designation from the EMEA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. In February 2006, the U.S. Food and Drug Administration (FDA) also approved an orphan drug designation for MT103 for the treatment of certain indolent B-cell lymphomas. MT103 specifically targets the CD19 antigen, which is present on B-cells and B cell-derived tumors but not on other types of blood cells or healthy tissues.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its a
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... of The Royal Marsden Hospital Manual of Clinical Nursing ... format that organises 15 key chapters into four key ... on areas such as risk management and preparing patients ... from the world-renowned UK centre of excellence, the Manual ...
... HealthDay Reporter , SUNDAY, April 3 (HealthDay News) -- Diabetes ... suggests an increased risk of cancer can be added to that ... had an 8 percent increased risk of developing cancer generally, while ... of prostate cancer were excluded from the calculation. The risk ...
... 4 (HealthDay News) -- Taking aspirin even once per month, ... a marked drop in the risk of developing pancreatic cancer, ... was linked to a 26 percent reduction in the risk ... of heart disease, was associated with an even greater drop ...
... be assessed by examining the epithelial cells found in ... the AACR 102nd Annual Meeting 2011, held April 2-6. ... provide a personalized assessment of breast cancer risk, said ... veterinary and animal sciences at the University of Massachusetts ...
... Prostate cancer is the second leading cause of cancer-related death ... reduced the number of deaths from the disease. By ... risk for aggressive disease or diagnosis at a young age, ... screening approach. For that reason, scientists have been looking for ...
... (March 29, 2011) Medicare coverage and nationwide ... as virtual colonoscopy, has tripled in recent years, according ... Journal of the American College of Radiology ... produce a three-dimensional visualization that permits a thorough and ...
Cached Medicine News:Health News:Patient's journey format drives new edition of vital student nurse manual 2Health News:Patient's journey format drives new edition of vital student nurse manual 3Health News:Add Cancer to Health Risks of Diabetes: Study 2Health News:Add Cancer to Health Risks of Diabetes: Study 3Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 2Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 3Health News:Breast milk may provide a personalized screen of breast cancer risk 2Health News:MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men 2Health News:Nationwide utilization of virtual colonoscopy triples, study suggests 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: